Polyethylene glycol


Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
Polyethylene glycol
Accession Number
Small Molecule
Approved, Vet approved

Polyethylene glycol is a polyether compound used for many purposes ranging from industrial manufacturing processes to medicine. PEG is the basis of a number of laxatives (e.g., macrogol-containing products, such as Movicol and polyethylene glycol 3350, or SoftLax, MiraLAX,ClearLAX, Osmolax or GlycoLax). Irrigation of the bowel with polyethylene glycol and electrolytes is included in bowel preparation therapy, normally indicated before a colonoscopy to ensure adequate visualization of the bowel. Therapeutic classification is as an Osmotic Laxative that works by drawing water into the lumen of the intestinal tract. Shown to decrease consistency and increase weight of stool in constipated patients at low doses.

  • Macrogol
  • Macrogol 3350
  • Macrogol 4000
  • Macrogol 6000
  • PEG
  • Polyethylene glycol 3350
  • Polyethylene glycol 4000
  • Polyethylene glycol 6000
Product Ingredients
IngredientUNIICASInChI Key
Polyoxyethylene 23 lauryl etherN72LMW566GNot AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GialaxKit1 g/1gOralPhlight Pharma, Llc2011-10-01Not applicableUs
Polyethylene Glycol 3350 NF PEGyLAXPowder, for solution17 g/17gOralMartin Ekwealor Pharmaceuticals, Inc.2013-12-16Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GavilaxPowder, for solution17 g/17gOralDirectrx2015-01-01Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/17gOralGolden State Medical Supply2013-02-082018-10-11Us
Polyethylene Glycol 3350Powder, for solution17 g/17gOralCardinal Health2006-05-242020-07-31Us
Polyethylene Glycol 3350Powder, for solution17 g/1OralMetrics, Inc.2006-05-242009-02-28Us
Polyethylene Glycol 3350Powder, for solution17 g/17gOralNucare Pharmaceuticals,inc.2006-09-06Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/1OralEmcure Pharmaceuticals Ltd.2011-09-28Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/17gOralProficient Rx LP2006-09-06Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/17gOralPaddock Laboratories, LLC2006-05-242020-10-31Us
Polyethylene Glycol 3350Powder1 g/1gOralPhysicians Total Care, Inc.2004-10-07Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/1OralREMEDYREPACK INC.2014-08-052018-05-04Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Basic Care ClearlaxPowder, for solution17 g/17gOralL. Perrigo Company2017-08-10Not applicableUs
Berkley and Jensen ClearlaxPowder, for solution17 g/17gOralBJWC2009-12-17Not applicableUs
BET-R-PrepPowder, for solution17 g/17gOralSatius Pharmaceuticals, Llc2017-11-27Not applicableUs
Care One ClearlaxPowder, for solution17 g/17gOralAmerican Sales Company2009-10-09Not applicableUs
ClarilaxPowder, for solutionOralPharmascience IncNot applicableNot applicableCanada
Clear LaxPowder, for solution17 g/17gOralMeijer Distribution Inc2009-10-06Not applicableUs
Clear LaxPowder, for solution17 g/17gOralH E B2009-10-08Not applicableUs
Clear LaxPowder, for solution17 g/17gOralMeijer Distribution2017-07-12Not applicableUs
Clear LaxPowder, for solution17 g/17gOralMeijer Distribution2009-10-062013-10-19Us
Clear Lax Original Prescription StrengthPowder, for solution17 g/17gOralHYVEE INC2009-10-112020-03-23Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aquasite DpsPolyethylene glycol (.2 %) + Dextran 70 (.1 %)Solution / dropsOphthalmicCiba Vision1993-12-312000-11-08Canada
Bi-peglytePolyethylene glycol (59.55 g) + Bisacodyl (5 mg) + Potassium chloride (0.76 g) + Sodium bicarbonate (1.69 g) + Sodium chloride (1.46 g) + Sodium sulfate (5.74 g)Kit; Powder, for solution; Tablet, delayed releaseOralPendopharm Division Of Pharmascience Inc2010-06-06Not applicableCanada
Clenz-LytePolyethylene glycol (236 g/4L) + Potassium chloride (2.97 g/4L) + Sodium bicarbonate (6.74 g/4L) + Sodium chloride (5.86 g/4L) + Sodium sulfate (22.74 g/4L)Powder, for solutionNasogastric; OralPaddock Laboratories, Inc.2010-06-072010-06-07Us
ColytePolyethylene glycol (857.69 mg) + Potassium chloride (10.65 mg) + Sodium bicarbonate (24.02 mg) + Sodium chloride (20.87 mg) + Sodium sulfate (81.2 mg)Powder, for solutionNasogastric; OralPendopharm Division Of Pharmascience Inc1986-12-31Not applicableCanada
ColytePolyethylene glycol (227.1 g/3.785L) + Potassium chloride (2.82 g/3.785L) + Sodium bicarbonate (6.36 g/3.785L) + Sodium chloride (5.53 g/3.785L) + Sodium sulfate decahydrate (21.5 g/3.785L)Powder, for solutionNasogastric; OralAlaven Pharmaceutical2010-09-012016-05-31Us
ColytePolyethylene glycol (240 g/4L) + Potassium chloride (2.98 g/4L) + Sodium bicarbonate (6.72 g/4L) + Sodium chloride (5.84 g/4L) + Sodium sulfate decahydrate (22.72 g/4L)Powder, for solutionNasogastricMEDA Pharmaceuticals2014-08-05Not applicableUs
Colyte with flavor packsPolyethylene glycol (240 g/4L) + Potassium chloride (2.98 g/4L) + Sodium bicarbonate (6.72 g/4L) + Sodium chloride (5.84 g/4L) + Sodium sulfate decahydrate (22.72 g/4L)Powder, for solutionNasogastric; OralAlaven Pharmaceutical1999-04-072016-08-31Us
Electropeg SolutionPolyethylene glycol (238.8 g) + Potassium chloride (3 g) + Sodium bicarbonate (6.7 g) + Sodium chloride (5.8 g) + Sodium sulfate (22.7 g)PowderOralTechnilab Pharma Inc.1998-04-201999-09-27Canada
GaviLyte - C TMPolyethylene glycol (240 g/278.26g) + Potassium chloride (2.98 g/278.26g) + Sodium bicarbonate (6.72 g/278.26g) + Sodium chloride (5.84 g/278.26g) + Sodium sulfate (22.72 g/278.26g)Powder, for solutionOralLupin Pharmaceuticals2009-01-06Not applicableUs
GaviLyte - NPolyethylene glycol (420 g/438.4g) + Potassium chloride (1.48 g/438.4g) + Sodium bicarbonate (5.72 g/438.4g) + Sodium chloride (11.2 g/438.4g)Powder, for solutionOralLupin Pharmaceuticals2009-05-28Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GialaxPolyethylene glycol (1 g/1g)KitOralPhlight Pharma, Llc2011-10-01Not applicableUs
PCP 100 KitPolyethylene glycol (17 g/17g) + Bisacodyl (5 mg/1) + Magnesium citrate (1.745 g/29.6mL) + Metoclopramide hydrochloride monohydrate (10 mg/1) + Petrolatum (0.76 g/1g)KitOralAsclemed Usa, Inc.2014-01-02Not applicableUs
PegPolyethylene glycol (55 g/100g) + Polyethylene glycol 400 (45 g/100g)CreamTopicalBiocellerex, Inc.2015-07-142016-01-05Us
Polyethylene Glycol 3350 NF PEGyLAXPolyethylene glycol (17 g/17g)Powder, for solutionOralMartin Ekwealor Pharmaceuticals, Inc.2013-12-16Not applicableUs
International/Other Brands
Fortrans / GlycoLax / TriLyte
CAS number



Used to treat and prevent constipation.

Associated Conditions
Associated Therapies

The pharmacological rationale for the use of polyethylene glycol (PEG) in gastroenterology is its inverse relation between molecular mass and intestinal absorbability, with practically no intestinal absorption at molecular masses exceeding 3000, its lack of intestinal enzymatic degradation or bacterial metabolism, and its water binding capacity.

Mechanism of action

Polyethylene glycol functions as an osmotic agent, causing excess water to be retained in the stool, stimulating a bowel movement.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Usually the high and intermediate molecular weight polyethylene glycol are poorly absorbed after oral administration.

Volume of distribution
Not Available
Protein binding
Not Available

Lack of intestinal enzymatic degradation or bacterial metabolism.

Route of elimination
Not Available
Half life
Not Available
Not Available

Oral LD50 is > 50 gm/Kg in mice, rats, and rabbits. In the event of overdosage, diarrhea would be the expected major event. Massive ingestion, prolonged IV infusion, and prolonged application of low weight PEG products have been associated with metabolic acidosis and renal injury. Hypercalcemia could also occur.

Affected organisms
Not Available
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Polyethylene glycol.
Abicipar PegolThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polyethylene glycol.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Polyethylene glycol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Polyethylene glycol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Polyethylene glycol.
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Polyethylene glycol.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Polyethylene glycol.
AclidiniumThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aclidinium.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Polyethylene glycol.
AgmatineThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Agmatine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available


General References
  1. Hammer HF, Hammer J, Gasche C: [Polyethylene glycol (Macrogol)--an overview of its use in diagnosis and therapy of gastrointestinal diseases]. Wien Klin Wochenschr. 2000 Jan 28;112(2):53-60. [PubMed:10703152]
  2. Muller-Lissner S: Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):391-401. doi: 10.1517/17425255.2013.773972. Epub 2013 Feb 21. [PubMed:23425050]
  3. PLENVU (polyethylene glycol 3350, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) US FDA 2018 Label [Link]
  4. PegaLAX (polyethylene glycol 3350) 2017 Canadian Prescribing Information [Link]
  5. NIH US National Library of Medicine MedlinePlus: Polyethylene Glycol 3350 Profile [Link]
  6. Electronic Medicines Compendium: PegLax (Macrogol 4000) Monograph [Link]
  7. NCBI StatPearls [Internet]: Bowel Preparation [Link]
External Links
PubChem Substance
ATC Codes
A06AD15 — MacrogolA06AD65 — Macrogol, combinations
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives
FDA label
Download (539 KB)
Download (710 KB)

Clinical Trials

Clinical Trials
0RecruitingSupportive CareDiverticulitis / Inflammatory Bowel Diseases (IBD) / Neoplasms, Colorectal / Surgical Site Infections1
1CompletedDiagnosticGastrointestinal Hemorrhage1
1CompletedTreatmentChronic Constipation1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentGastric Emptying / Healthy Volunteers1
1Not Yet RecruitingTreatmentPharmacokinetics1
1, 2CompletedTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Problems1
1, 2Not Yet RecruitingScreeningBowel Preparation for Pediatric Colonoscopy / Bowel preparation therapy1
1, 2RecruitingTreatmentCrohn's Disease (CD)1
1, 2Unknown StatusTreatmentAnti-Biotic Resistance / Klebsiella Pneumoniae1
2Active Not RecruitingTreatmentBowel Preparation Before Colonoscopy1
2CompletedDiagnosticMalignant Neoplasm of Colon1
2CompletedOtherBowel preparation therapy1
2CompletedOtherColon Prep for Colonoscopy1
2CompletedScreeningHealthy Volunteers1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentMalignant Neoplasm of Colon1
2RecruitingTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Disorder1
2RecruitingTreatmentCrohn's Disease (CD)1
2, 3RecruitingTreatmentClostridium Difficile1
3CompletedNot AvailableBowel Preparation for Colonoscopy1
3CompletedNot AvailableColonoscopy1
3CompletedDiagnosticBowel Preparation for Colonoscopy1
3CompletedDiagnosticBowel Preparation, Efficacy, Tolerability, Safety1
3CompletedDiagnosticPatients Who Receive Colonoscopy1
3CompletedOtherBowel Cleansing Efficacy / Unrecognized Condition1
3CompletedScreeningCarcinoma, Colorectal / Colon Cleansing / Colorectal Cancers1
3CompletedSupportive CareColon Adenomas / Colorectal Cancers1
3CompletedSupportive CareColonic Diseases / Diabetes Mellitus (DM)1
3CompletedTreatmentBowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel1
3CompletedTreatmentBowel preparation therapy / Colonoscopy / Endoscopy1
3CompletedTreatmentColon Cleansing1
3CompletedTreatmentColon Diseases / Colonoscopy Preparation1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentMalignant Neoplasm of Colon1
3Not Yet RecruitingTreatmentConstipation - Functional1
3Not Yet RecruitingTreatmentConstipation / Critical Illness1
3Not Yet RecruitingTreatmentFunctional Constipation1
3RecruitingOtherDigestive System Diseases1
3RecruitingTreatmentBowel Preparation Before Colonoscopy1
3Unknown StatusDiagnosticColonoscopy1
4Active Not RecruitingOtherColorectal Polyps1
4CompletedNot AvailableColonoscopy1
4CompletedBasic ScienceFunctional Constipation / Irritable Bowel Syndrome Characterized by Constipation1
4CompletedDiagnosticColonoscopy Preparation1
4CompletedOtherChronic Constipation1
4CompletedOtherSmall Bowel Diseases1
4CompletedScreeningAdenoma Detection Rate / Bowel Preparation Scale1
4CompletedScreeningColorectal Cancers1
4CompletedTreatmentBowel Preparation for Colonoscopy1
4CompletedTreatmentChronic Constipation1
4CompletedTreatmentColon Cleansing1
4CompletedTreatmentColon Cleansing for Colonoscopy1
4CompletedTreatmentColonoscopy Preparation1
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentGastrointestinal Diseases1
4CompletedTreatmentIntestinal Cancer1
4CompletedTreatmentMalignant Neoplasm of Colon1
4CompletedTreatmentOpioid Induced Constipation (OIC)1
4CompletedTreatmentPreparation for Colonoscopy1
4CompletedTreatmentSubjets Requiring a Colonoscopy1
4Enrolling by InvitationDiagnosticColonoscopy1
4Not Yet RecruitingOtherCleansing Quality of the Colon1
4RecruitingDiagnosticBowel Preparation Solutions1
4RecruitingDiagnosticBowel preparation therapy1
4RecruitingDiagnosticColon Adenomas / Colon Lesion / Colon Polyps1
4RecruitingDiagnosticPolyethylene Glycol / Sodium Phosphate1
4RecruitingDiagnosticUlcerative Colitis1
4RecruitingHealth Services ResearchColorectal Cancers1
4RecruitingOtherCapsule Endoscopy / Gluten Enteropathy / Inflammatory Bowel Diseases (IBD)1
4RecruitingPreventionPostoperative Bowel Movement / Postoperative Passage of Flatus1
4RecruitingTreatmentAcute-On-Chronic Liver Failure / Hepatic Encephalopathy1
4RecruitingTreatmentChronic Functional Constipation / Functional Constipation1
4RecruitingTreatmentConstipation / Peritoneal dialysis complication1
4RecruitingTreatmentFissure in Ano1
4RecruitingTreatmentHepatic Encephalopathy1
4TerminatedNot AvailableBowel preparation therapy1
4TerminatedNot AvailableColonoscopy Preparation1
4TerminatedDiagnosticColonoscopy Failure / Poor Bowel Preparation1
4TerminatedSupportive CareConstipation / Malignancies1
4Unknown StatusNot AvailableClostridium Difficile Colitis1
4Unknown StatusNot AvailableMalignant Neoplasm of Colon / Rectal Carcinoma1
4Unknown StatusHealth Services ResearchColonoscopy1
4Unknown StatusTreatmentConstipation1
4WithdrawnTreatmentDiurnal Enuresis1
4WithdrawnTreatmentNocturnal Enuresis1
Not AvailableCompletedNot AvailableColonoscopy Preparation2
Not AvailableCompletedNot AvailableEase of Bowel Preparation and Patient Tolerability / Efficacy of Bowel Preparation1
Not AvailableCompletedNot AvailableEffectiveness of SMS to Fix PC Interval1
Not AvailableCompletedNot AvailableHyponatremia1
Not AvailableCompletedNot AvailableSpinal Cord Injuries (SCI)1
Not AvailableCompletedNot AvailableThe Timing of Bowel Preparation in Outpatient Colonoscopy1
Not AvailableCompletedDiagnosticBowel preparation therapy1
Not AvailableCompletedDiagnosticColonoscopy1
Not AvailableCompletedDiagnosticDiabetes Mellitus (DM)1
Not AvailableCompletedHealth Services ResearchAcute Kidney Injury (AKI)1
Not AvailableCompletedOtherBowel preparation therapy1
Not AvailableCompletedPreventionFunctional Disorder of Intestine1
Not AvailableCompletedPreventionHemolytic-uremic Syndrome (HUS) / Hemorrhagic Colitis / Intestinal Infection Due to E. Coli / Intestinal Infectious Disease1
Not AvailableCompletedPreventionPost Procedural Constipation1
Not AvailableCompletedScreeningUlcerative Colitis1
Not AvailableCompletedTreatmentConstipation1
Not AvailableCompletedTreatmentHepatic Encephalopathy / Liver Cirrhosis / Portosystemic Encephalopathy / PSE1
Not AvailableCompletedTreatmentInflammatory Bowel Diseases (IBD)1
Not AvailableCompletedTreatmentUrge Syndrome1
Not AvailableRecruitingNot AvailableDigestive Illness1
Not AvailableRecruitingBasic ScienceMicrobiota1
Not AvailableRecruitingDiagnosticCTE1
Not AvailableRecruitingDiagnosticColonoscopy1
Not AvailableRecruitingPreventionRectal Carcinoma1
Not AvailableRecruitingScreeningColonoscopy1
Not AvailableTerminatedTreatmentColonoscopy1
Not AvailableTerminatedTreatmentConstipation1
Not AvailableTerminatedTreatmentFecal Incontinence1
Not AvailableUnknown StatusDiagnosticBowel Preparation for Colonoscopy1
Not AvailableUnknown StatusDiagnosticBowel preparation therapy1
Not AvailableUnknown StatusDiagnosticColonic Adenomas1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1
Not AvailableWithdrawnTreatmentAltered Mental Status / AMS / HE / Hepatic Encephalopathy / Liver Cirrhosis1
Not AvailableWithdrawnTreatmentColonoscopy1


Not Available
Not Available
Dosage forms
Solution / dropsOphthalmic
Kit; powder, for solution; tablet, delayed releaseOral
Powder, for solutionOral100 %
Powder, for solutionTopical17 g/1
Powder, for solutionNasogastric
PowderTopical17 g/17g
KitOral1 g/1g
PowderOral17 g/17g
Aerosol, meteredNasal
Powder, for solutionOral
PowderOral1 g/1g
Powder, for solutionOral1 g/1g
Powder, for solutionOral17 g/1
Powder, for solutionOral60 g/1L
Powder, for solutionOral17 g/1g
Powder, for solutionOral17 g/1d
Powder, for solutionOral17 g/17g
Powder, for solutionOral
Spray, meteredNasal
Powder, for solutionNasogastric; Oral
Not Available
Patent NumberPediatric ExtensionApprovedExpires (estimated)
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available


Mass Spec (NIST)
Not Available
Not Available


Not classified

Drug created on October 29, 2015 12:17 / Updated on November 20, 2019 12:31